Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial

托珠单抗 医学 巨细胞动脉炎 中止 强的松 泼尼松龙 安慰剂 内科学 糖皮质激素 临床试验 随机对照试验 不利影响 外科 血管炎 病理 类风湿性关节炎 替代医学 疾病
作者
John H. Stone,Jian Han,Martin Aringer,Daniel Engelbert Blockmans,Elisabeth Brouwer,Maria C. Cid,Bhaskar Dasgupta,Juergen Rech,Carlo Salvarani,Robert Spiera,Sebastian Unizony,Min Bao
出处
期刊:The Lancet Rheumatology [Elsevier]
卷期号:3 (5): e328-e336 被引量:40
标识
DOI:10.1016/s2665-9913(21)00038-2
摘要

Background The combination of tocilizumab plus a glucocorticoid taper is effective in maintaining clinical remission without requiring additional glucocorticoid therapy in patients with giant cell arteritis, as shown in part one of the Giant Cell Arteritis Actemra (GiACTA) trial. However, the duration of the tocilizumab effect after discontinuation is unknown. Here, we explored the maintenance of efficacy 1 year after discontinuation of tocilizumab treatment, the effectiveness of retreatment with tocilizumab after relapse, and the long-term glucocorticoid-sparing effect of tocilizumab. Methods In part one of the GiACTA trial, 251 patients were randomly assigned (2:1:1:1) to receive subcutaneous tocilizumab (162 mg) once a week or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52 weeks. Patients in clinical remission stopped masked injections at 1 year (the conclusion of part one). In part two, treatment was at the investigators' discretion and could consist of no treatment, tocilizumab, glucocorticoids, methotrexate, or combinations of these, for two years. Maintenance of efficacy as assessed by clinical remission (defined as absence of relapse determined by the investigator), cumulative glucocorticoid dose, and long-term safety were exploratory objectives in part two of the trial. This trial is registered at ClinicalTrials.gov, NCT01791153. Findings 215 patients participated in part two of the trial; 81 patients who were randomly assigned to tocilizumab once a week in part one were in clinical remission after 1 year, of whom 59 started part two on no treatment. 25 of these 59 patients (42%) maintained tocilizumab-free and glucocorticoid-free clinical remission throughout part two. Median (95% CI) cumulative glucocorticoid doses over 3 years were 2647 mg (1987–3507) for tocilizumab once a week, 3948 mg (2352–5186) for tocilizumab-every-other-week, 5277 mg (3944–6685) for placebo with a 26-week prednisone taper, and 5323 mg (3900–6951) for placebo with a 52-week prednisone taper (van Elteren p≤0·001, tocilizumab once a week vs placebo groups; p<0·05, tocilizumab-every-other-week vs placebo groups). Tocilizumab-based regimens restored clinical remission among patients who experienced relapse in part two and were treated (median time to remission: 15 days for tocilizumab alone [n=17]; 16 days for tocilizumab plus glucocorticoids [n=36]; and 54 days for glucocorticoids alone [n=27]). No new or unexpected safety findings were reported over the full 3 years of the study. Interpretation Giant cell arteritis remains a chronic disease that entails ongoing management and careful vigilance for disease relapse, but continuous indefinite treatment with immunosuppressive drugs is not required for all patients. A substantial proportion of patients treated with tocilizumab for one year maintain drug-free remission during the two years after tocilizumab cessation. For patients who experience relapse, tocilizumab can be used to manage relapses, but it remains prudent to include prednisone for patients who experience relapse because of the risk for vision loss. Funding F Hoffmann-La Roche. The combination of tocilizumab plus a glucocorticoid taper is effective in maintaining clinical remission without requiring additional glucocorticoid therapy in patients with giant cell arteritis, as shown in part one of the Giant Cell Arteritis Actemra (GiACTA) trial. However, the duration of the tocilizumab effect after discontinuation is unknown. Here, we explored the maintenance of efficacy 1 year after discontinuation of tocilizumab treatment, the effectiveness of retreatment with tocilizumab after relapse, and the long-term glucocorticoid-sparing effect of tocilizumab. In part one of the GiACTA trial, 251 patients were randomly assigned (2:1:1:1) to receive subcutaneous tocilizumab (162 mg) once a week or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52 weeks. Patients in clinical remission stopped masked injections at 1 year (the conclusion of part one). In part two, treatment was at the investigators' discretion and could consist of no treatment, tocilizumab, glucocorticoids, methotrexate, or combinations of these, for two years. Maintenance of efficacy as assessed by clinical remission (defined as absence of relapse determined by the investigator), cumulative glucocorticoid dose, and long-term safety were exploratory objectives in part two of the trial. This trial is registered at ClinicalTrials.gov, NCT01791153. 215 patients participated in part two of the trial; 81 patients who were randomly assigned to tocilizumab once a week in part one were in clinical remission after 1 year, of whom 59 started part two on no treatment. 25 of these 59 patients (42%) maintained tocilizumab-free and glucocorticoid-free clinical remission throughout part two. Median (95% CI) cumulative glucocorticoid doses over 3 years were 2647 mg (1987–3507) for tocilizumab once a week, 3948 mg (2352–5186) for tocilizumab-every-other-week, 5277 mg (3944–6685) for placebo with a 26-week prednisone taper, and 5323 mg (3900–6951) for placebo with a 52-week prednisone taper (van Elteren p≤0·001, tocilizumab once a week vs placebo groups; p<0·05, tocilizumab-every-other-week vs placebo groups). Tocilizumab-based regimens restored clinical remission among patients who experienced relapse in part two and were treated (median time to remission: 15 days for tocilizumab alone [n=17]; 16 days for tocilizumab plus glucocorticoids [n=36]; and 54 days for glucocorticoids alone [n=27]). No new or unexpected safety findings were reported over the full 3 years of the study. Giant cell arteritis remains a chronic disease that entails ongoing management and careful vigilance for disease relapse, but continuous indefinite treatment with immunosuppressive drugs is not required for all patients. A substantial proportion of patients treated with tocilizumab for one year maintain drug-free remission during the two years after tocilizumab cessation. For patients who experience relapse, tocilizumab can be used to manage relapses, but it remains prudent to include prednisone for patients who experience relapse because of the risk for vision loss.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jasper应助ertredffg采纳,获得10
刚刚
Kk完成签到,获得积分20
刚刚
感人的心发布了新的文献求助10
1秒前
羊六一发布了新的文献求助10
1秒前
齐桓完成签到,获得积分10
2秒前
竹筏过海应助科研通管家采纳,获得30
3秒前
3秒前
小蘑菇应助科研通管家采纳,获得10
3秒前
zho应助科研通管家采纳,获得10
3秒前
孤独的根号4完成签到,获得积分10
3秒前
在水一方应助科研通管家采纳,获得10
3秒前
黄昏完成签到,获得积分10
3秒前
香蕉觅云应助科研通管家采纳,获得10
4秒前
小二郎应助科研通管家采纳,获得10
4秒前
4秒前
Endlessway应助科研通管家采纳,获得20
4秒前
4秒前
bymjxx应助科研通管家采纳,获得10
4秒前
Jasper应助科研通管家采纳,获得10
4秒前
小二郎应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
4秒前
秃驴完成签到,获得积分10
5秒前
科研通AI2S应助jar7989采纳,获得10
5秒前
实验菜菜君完成签到 ,获得积分10
5秒前
那些兔儿完成签到 ,获得积分10
6秒前
四爷完成签到,获得积分10
6秒前
小二郎应助感人的心采纳,获得10
6秒前
玉麒麟完成签到,获得积分0
6秒前
炙热听安完成签到,获得积分10
7秒前
7秒前
朴实问筠完成签到 ,获得积分10
8秒前
hhhh发布了新的文献求助10
8秒前
Kelly发布了新的文献求助10
8秒前
yao chen完成签到,获得积分10
9秒前
min17发布了新的文献求助10
10秒前
炙热听安发布了新的文献求助10
10秒前
10秒前
科研1完成签到,获得积分20
10秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3244993
求助须知:如何正确求助?哪些是违规求助? 2888654
关于积分的说明 8254529
捐赠科研通 2557066
什么是DOI,文献DOI怎么找? 1385741
科研通“疑难数据库(出版商)”最低求助积分说明 650214
邀请新用户注册赠送积分活动 626422